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Diabetes is associated with increased mortality from severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2). Given literature suggesting a potential association between SARS-CoV-2 infection and dia-
betes induction, we examined pancreatic expression of angiotensin-converting enzyme 2 (ACE2), the key en-
try factor for SARS-CoV-2 infection. Specifically, we analyzed five public scRNA-seq pancreas datasets and
performed fluorescence in situ hybridization, western blotting, and immunolocalization for ACE2 with exten-
sive reagent validation on normal human pancreatic tissues across the lifespan, as well as those from coro-
navirus disease 2019 (COVID-19) cases. These in silico and ex vivo analyses demonstrated prominent expres-
sion of ACE2 in pancreatic ductal epithelium and microvasculature, but we found rare endocrine cell
expression at the mRNA level. Pancreata from individuals with COVID-19 demonstrated multiple thrombotic
lesions with SARS-CoV-2 nucleocapsid protein expression that was primarily limited to ducts. These results
suggest SARS-CoV-2 infection of pancreatic endocrine cells, via ACE2, is an unlikely central pathogenic
feature of COVID-19-related diabetes.
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic caused by
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
has created a global healthcare crisis (Mercatelli and Giorgi,
2020). With infections continuing to rise in many countries and
the potential for continuing viral persistence in the absence of
a vaccine, there is an urgent need to better understand SARS-
CoV-2-mediated pathology. Key to this are efforts examining hu-
man tissues potentially susceptible to infection.
While initial reports primarily focused on pulmonary and cardio-
vascular manifestations, other organs including the kidney, brain,
and intestines, as well as the pancreas, have since been noted as
affected by this disorder’s pathophysiology (Connors and Levy,
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2020; Fox et al., 2020; Hanley et al., 2020; Lee et al., 2020b; Liu
et al., 2020; Menter et al., 2020; Rapkiewicz et al., 2020; Varga
et al., 2020; Wang et al., 2020; Wichmann et al., 2020). Indeed,
recent reports have raised the question of whether SARS-CoV-2
might infect the pancreas and possibly potentiate or exacerbate
diabetes in either of its predominant forms, type 1 or type 2 dia-
betes (T1D or T2D, respectively). These studies noted elevated
serum levels of the exocrine pancreatic enzymes, amylase and
lipase, as well as development or worsening of hyperglycemia in
SARS-CoV-2-positive individuals (Wang et al., 2020), high preva-
lence of diabetic ketoacidosis in people hospitalized with COVID-
19 (Goldman et al., 2020; Li et al., 2020), and increased COVID-
19-induced mortality in those with T1D and T2D (Barron et al.,
2020; Holman et al., 2020). Reports also include increased inci-
denceof new-onset T1D in specific geographic clusters (Unsworth
et al., 2020), case reports linking the timing of T1Donset toCOVID-
19 (Marchand et al., 2020), and pancreatic expression of angio-
tensin-converting enzyme 2 (ACE2) through which SARS-CoV-2
could gain access to cells (Chen and Hao, 2020), potentially
including insulin-producing b cells (Lee et al., 2020b; Yang et al.,
2020). Such reports have collectively led to the hypothesis that
SARS-CoV-2 expression in b cells may potentiate or exacerbate
T1D or T2D. However, ACE2 expression in the human pancreas
is only partially characterized, with conflicting results in both the
endocrineandexocrinecompartments (Fignani et al., 2020;Hikmet
et al., 2020; Lee et al., 2020b; Yang et al., 2010, 2020). Indeed, the
most cited report (Yang et al., 2010) utilized a single unspecified
antibody, was limited in the number of tissue samples and cases,
and lacked reagent validation.
To better understand the potential impact of SARS-CoV-2 on
diabetes, we performed an extensive investigation of the human
pancreas, with particular focus on its endocrine component, the
islet of Langerhans. Specifically, we carried out an integration
analysis of publicly available single-cell RNA sequencing
(scRNA-seq) data from isolated human islets, coupled these
findings with direct visualization of gene and protein expression
of ACE2 using single molecular fluorescence in situ hybridization
(smFISH), chromogen-based immunohistochemistry (IHC), and
multicolor immunofluorescence (IF) in human tissue. Impor-
tantly, we employed a multi-center approach to the selection,
testing, and validation of four commercially available ACE2 anti-
bodies by IHC and immunoblot using known ACE2-positive tis-
sues in addition to the pancreas. Finally, we analyzed SARS-
CoV-2 nucleocapsid protein (NP) expression in autopsy-derived
tissues from individuals with COVID-19 to assess whether the vi-
rus was detected in pancreatic islet endocrine cells.
RESULTS AND DISCUSSION
ACE2 and TMPRSS2 Gene Expression Is Low in Human
Pancreatic Endocrine Cells
Diabetes, obesity, and advanced age increase the risk of COVID-
19 mortality (Zhou et al., 2020). Autopsy studies of individuals in-
fected with SARS-CoV-2 demonstrate systemic viral dissemina-
tion with persistence in multiple organs, including the lungs and
kidneys (Hanley et al., 2020; Liu et al., 2020; Menter et al., 2020;
Wichmann et al., 2020), but there was an apparent limitation of
pronounced inflammatory alterations to the lung and reticulo-
endothelial system (Dorward et al., 2020). Recent studies (Barron
et al., 2020; Fignani et al., 2020; Goldman et al., 2020; Holman
et al., 2020; Li et al., 2020; Marchand et al., 2020; Unsworth
et al., 2020; Wang et al., 2020) spurred interest in ACE2 expres-
sion in the pancreas, particularly the endocrine compartment, to
address a potential relationship between diabetes and COVID-
19, including the potential for either direct b cell infection or b
cell damage via indirect mechanisms. To date, studies of ACE2
expression in the pancreas have been limited and contradictory,
and analysis of autopsy specimens from COVID-19 cases have
not been published, likely due to challenges associated with tis-
sue procurement and post-mortem autolysis.
SARS-CoV-2 entry into cells via the ACE2 receptor requires S
protein priming by the mucosal serine proteases (Lee et al.,
2020b; Zang et al., 2020). We thus investigated expression pat-
terns of ACE2 and several proteases linked with SARS-CoV-2
processing by conducting an integrated analysis of scRNA-seq
data from five public datasets including 22 non-diabetic and 8
T2D individuals (Baron et al., 2016; Gr€un et al., 2016; Lawlor
et al., 2017; Muraro et al., 2016; Segerstolpe et al., 2016). This
analysis revealed a low frequency of ACE2-expressing cells
and low ACE2 expression levels in the majority of islet cell sub-
sets (Figures 1A and 1B). In islets from donors without diabetes,
ACE2 was expressed in <2% of endocrine, endothelial, and
select innate immune cells. ACE2 was detectable in 4.11% of
acinar cells and 5.54% of ductal cells in non-diabetic donors
as compared to 8.07% of acinar and 8.13% of ductal cells in do-
nors with T2D (Figures 1A and 1B; Table S1). Expression levels of
ACE2were not different between non-diabetic donors and those
with T2D in any of the islet cell subtypes (Figure 1A).
We next investigated the expression patterns of the serine
protease TMPRSS2, which is thought to be the main serine pro-
tease required for SARS-CoV-2 infectivity. TMPRSS2 was
detectable in 53.73% of acinar and 50.55% of ductal cells in do-
nors without diabetes, and 71.43% of acinar and 58.74% of
ductal cells in donors with T2D (Figure 1C; Table S1). Apart
from a cells, which demonstrated 16.55% positivity in non-dia-
betic donors and 32.07% positivity in donors with T2D,
TMPRSS2 expression was low in the majority of other endocrine
cell subsets (Figure 1C). TMPRSS2was detectable in 5.46% of b
cells, and neitherACE2 nor TMPRSS2 expression differed signif-
icantly in b cells from non-diabetic versus T2D donors (Figures
1A, 1C, S1A, and S1B). TMPRSS2 showed higher relative
expression levels in ductal and acinar cells compared to b cells
(adjusted p = 1.31 3 10291 and p < 1 3 10300, respectively),
and was detectable in an elevated proportion of these cells in
non-diabetic donors (p < 0.05) (Figures 1C and 1D). The fre-
quency and expression of ACE2 and TMPRSS2 relative to a sub-
set of cellular identity marker genes across each of the analyzed
cell populations highlight, in general, the low expression of ACE2
and TMPRSS2 across pancreatic cells (Figure 1E). We also
analyzed ACE2 and TMPRSS2 levels relative to an expanded
list of highly expressed genes in a and b cells, including GCG,
TTR, SCG2, INS, IAPP, and PDX1 (Figures 1F and 1G).
Because the expression of ACE2 in combination with an asso-
ciated protease appears to be required for cellular entry (Lee
et al., 2020b; Zang et al., 2020), we calculated the percentage
of each cell type that expressed both ACE2 and TMPRSS2.
Notably, only 0.24% and 0.10% of a cells and b cells were pos-
itive for ACE2 and TMPRSS2 in islets from donors without
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diabetes, while no a or b cells from donors with T2D expressed
both (Table S2). Fewer than 4% of acinar and ductal cells in do-
nors without diabetes were positive for ACE2 and TMPRSS2,
while co-expressionwas observed in 8.07%and 6.10%of acinar
and ductal cells, respectively, in donors with T2D (Table S2).
We also investigated expression patterns for other SARS-CoV-
2-associated proteases, including TMPRSS4, CTSL, ADAM17,
and TMPRSS11D (Table S1; Figures S1C–S1H). In addition, we
quantitated the percentage of cells that co-expressed ACE2 and
each of these proteases (Table S2). TMPRSS4 was expressed in
a similar proportion of a and b cells; however, relative expression
levels tended to be low in the endocrine pancreas (Figures S1C
Figure 1. SARS-CoV-2-Associated Gene
Expression in Isolated Human Pancreatic Is-
lets
(A) Bar graph showing the percentage of cells with
detectableACE2 in islets frompancreata of donors
with (n = 2,705 cells) and without type 2 diabetes
(n = 12,185 cells).
(B) Violin plot showing the distribution of ACE2
normalized expression in islet cells from pancreata
of donors without diabetes.
(C) Bar graph showing the percentage of cells with
detectable TMPRSS2 in islets isolated from pan-
creata of donors with (n = 2,705 cells) and without
type2diabetes (n=12,185cells); *adjustedp<0.05,
paired Student’s t test for indicated comparisons.
(D) Violin plot showing the distribution of
TMPRSS2 normalized expression in islets cells
from pancreata of donors without diabetes;
***adjusted p < 0.001, Wilcoxon rank-sum tests.
Bonferroni corrections were used to adjust for
multiple comparisons.
(E) Dot plot of ACE2 and TMPRSS2 expression
compared with cell-type-enriched genes in islets
from pancreata of donors without type 2 diabetes
(n = 12,185 cells). The size of each dot indicates
the percentage of cells in a given population ex-
pressing the indicated gene. The dot color repre-
sents the scaled average expression.
(F) Violin plot showing the relative expression of
ACE2 and TMPRSS2 in islet a cells from pancreata
of donors without diabetes (n = 3,770 cells)
compared with select a cell-enriched genes.
(G)Violin plot showing the relative expression of
ACE2 and TMPRSS2 in islet b cells from pancreata
of donors without diabetes (n = 2,985 cells)
compared with select b cell-enriched genes.
Related to Tables S1 and S2 and Figure S1.
and S1D). CTSL and ADAM17 were de-
tected at higher levels in a and b cells (Fig-
ures S1E and S1F). The relative expression
of TMPRSS11Dwas low inmost cell types
examined (Figure S1G). Within the b cells,
only CTSL showed higher expression in
donors with T2D compared to donors
without diabetes (adjusted p = 8.94 3
1032; Figure S1H). Notably, less than 1%
of b cells expressed ACE2 in combination
with any of these identified proteases
(Table S2).
To visualize ACE2 and TMPRSS2 mRNA expression pat-
terns in situ, we used smFISH on non-diabetic, SARS-CoV-
2-negative, ‘‘normal’’ human pancreata from seven donors
across a wide age-span (Table S3) with duodenum, ileum,
and kidney used as positive controls (Figures S2A and S2B).
ACE2 mRNA was observed in pancreatic ducts, acinar tissue,
and CD34+ endothelial cells (Figures 2A and 2B), but was
observed to a much lesser extent in the islet endocrine cells
(Figure 2C). TMPRSS2 mRNA showed a similar pattern
but was expressed at higher frequency (Figure 2). We
observed limited expression of TMPRSS2 and/or ACE2 in in-
sulin-positive b cells (Figure 2C, inset), which was consistent
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with quantification of ACE2 and TMPRSS2 expression and
co-expression from scRNA-seq data (Table S2). smFISH
analysis of other SARS-CoV-2-associated proteases revealed
TMPRSS4 mRNA in the exocrine pancreas, with rare
TMPRSS4 expression within the islet, while CTSL, ADAM17,
and TMPRSS11D expression was observed in both the endo-
crine and exocrine pancreas (Figures S2C–S2F).
Figure 2. Single Molecular Fluorescent In
Situ Hybridization-Based Validation of
SARS-CoV-2-Associated Gene Expression
in Human Pancreas
(A) Representative images of smFISH for ACE2
and TMPRSS2 mRNA in human pancreatic tissue
sections counterstained for insulin. Inset highlights
mRNA distribution in pancreatic ducts; scale bars,
20 mm. The lower image is highmagnification of the
boxed region in the merged panel.
(B) Representative smFISH images showing the
presence of ACE2 and TMPRSS2 in CD34-positive
cells in human pancreatic tissue sections; scale
bars, 10 mm. The lower image is high magnification
of the boxed region in the merged panel.
(C) Representative images of smFISH for ACE2
and TMPRSS2 mRNA in human pancreatic tissue
sections counterstained for insulin. Inset highlights
distribution in the endocrine pancreas; scale bars,
20 mm. The lower image is highmagnification of the
boxed region in the merged panel.
Related to Figure S2.
Extensive Reagent Validation
Confirms High Level of ACE2
Protein Expression in the Human
Pancreas
Information regarding ACE2 protein
expression in pancreatic tissue sections
remains limited and unfortunately contra-
dictory. A 2010 study on SARS-CoV and
its relationship with diabetes interrogated
ACE2 expression in a single donor (43
years of age), with an unspecified anti-
body, and reported weak ACE2 staining
in exocrine tissues but pronounced
expression in pancreatic islets (Yang
et al., 2010). Fignani et al. (2020) recently
described heterogenous ACE2 expres-
sion across donors, pancreatic lobes,
and islets, and identified three main
ACE2-expressing cell types in formalin
fixed, paraffin embedded (FFPE) pancre-
atic sections from seven donors (aged
22–59 years) probed with three ACE2 an-
tibodies (MAB933, ab15348, and
ab108252): endothelial cells and peri-
cytes, ductal cells, and in an analysis of
128 islets, b cells that often presented
with a granular staining pattern, partially
overlapping with insulin. In contrast, an
analysis of tissue microarrays containing
pancreatic FFPE sections from 10 donors
(aged 30–79 years) utilizing two ACE2 antibodies (MAB933 and
HPA000288) reported ACE2 expression restricted to endothelial
cells and pericytes and interlobular ducts while ACE2 was not
detectable in islets, acinar glandular cells, intercalated ducts,
or intralobular ducts (Hikmet et al., 2020). This study, together
with a publicly available preprint employing six ACE2 antibodies
(Lee et al., 2020a), is noteworthy for the broad range of major
ll
Short Article
4 Cell Metabolism 32, 1–11, December 1, 2020
Please cite this article in press as: Kusmartseva et al., Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Indi-
viduals with COVID-19, Cell Metabolism (2020), https://doi.org/10.1016/j.cmet.2020.11.005
human tissues and organs investigated as well as the delineation
of mostly shared but, also, some distinctive ACE2 antibody
staining properties. In light of these diverging observations, it is
imperative to utilizemultiple ACE2 antibodies on larger donor co-
horts to gather a comprehensive description of ACE2 expression
in the pancreas.
We selected four widely referenced, commercially available an-
tibodies recognizing specific epitopes and both the short and long
isoforms of the ACE2 protein (Figure 3A) (Blume et al., 2020; Ng
et al., 2020; Onabajo et al., 2020) to evaluate by immunoblot
(Figures 3B, S3A, and S3B) using protein extracts from three
non-diabetic, SARS-CoV-2-negative, ‘‘normal’’ pancreas donors
(Table S3). ACE2 is an 805 amino acid protein (UniProt Q9BYF1)
with a theoretical molecular mass of 94.2 kDa but an actual
Figure 3. ACE2 Protein Is Readily Detected
in Normal Human Pancreas with Its Expres-
sion Largely Restricted to Ductal andMicro-
vascular Structures
(A) ACE2 protein structure illustrating the location
of respective antibody directed antigen sites. SP,
signal peptide; TM, transmembrane domain; CD,
cytoplasmic domain.
(B) Immunoblot analysis of four commercially
available ACE2 antibodies using total pancreas
lysates from three control organ donors (p1–p3)
with accompanying Actin labeling. 120 and 37
indicate the molecular weight (in kDa) of ACE2 and
Actin, respectively.
(C) Representative IHC images of human pancreas
tissue sections stained for ACE2 and insulin using
four commercially available ACE2 antibodies.
Scale bars, 200 mm. d, duct; mv, microvasculature.
Related to Table S3 and Figures S3 and S4.
mass of 120 kDa due to glycosylation at
N terminus sites (Tipnis et al., 2000).
Accordingly, a pronounced 120 kDa
band was readily visualized by AF933 and
ab108252 while ab15348 and especially
MAB933 revealed a much weaker band
(Figures 3B and S3A). Nevertheless, in our
efforts, all four antibodies demonstrated
robust and essentially commensurate
staining in human duodenum and kidney
FFPE sections (Figure S3C), consistent
with two recent reports (Hikmet et al.,
2020; Lee et al., 2020a).
We next visualized ACE2 via chro-
mogen-based IHC in FFPE pancreata
from non-diabetic, SARS-CoV-2-negative,
‘‘normal’’ donors using all four antibodies
andconsistentlyobservedpositivestaining
in the microvasculature and ductal epithe-
lium (Figure 3C). To further validate speci-
ficity, we utilized a peptide-blocking assay
wherein ab108252was pre-incubatedwith
an ACE2 peptide prior to IHC staining (Fig-
ure S3D). Takingwestern blot and IHC vali-
dation into account, ab108252 produced a
clearly detectable 120 kDa band (Figures 3B and S3A) and crisp in
situ staining (Figures 3C andS3C) that was completely blocked by
pre-incubationwith theACE2peptide (FigureS3D). This isamono-
clonal antibody, which offers a high degree of specificity and con-
sistencybetween lots. Hence,weelected to use ab108252 in sub-
sequent IHC and IF assays.
Human Pancreatic Expression of ACE2 Protein Is
Primarily Detected in the Duct Epithelium and
Microvasculature Across the Lifespan and Positively
Associated with Obesity
To quantitatively evaluate pancreatic ACE2 protein expression,
an FFPE tissue cross-section from each of 36 SARS-CoV-2-
negative donors without diabetes (aged 0–72 years; Table S3)
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Figure 4. ACE2 Protein Expression Is Evident in Normal Pancreata throughout the Human Lifespan and Correlates with BMI
(A) Scheme of the experimental setup illustrating human pancreatic tissue processing, whole-stained slide imaging, and machine learning algorithm application
for the generation of ACE2 protein expression data.
(legend continued on next page)
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was stained for insulin and ACE2 (ab108252) and scanned to
produce a whole-slide image. Co-localization of ACE2 protein
with insulin was not observed (Figures 3C and S4A). The tissue
area staining positive for ACE2 was analyzed using the HALO
area quantification algorithm (Figure 4A). Body mass index
(BMI)-matched donors were binned into six age groups: neonate
(0–0.25 years, n = 6), infant and toddler (0.25–2 years, n = 6), child
(2–11 years, n = 6), adolescent (11–15 years, n = 6), young adult
(20–33 years, n = 6), and senior adult (51–72 years, n = 6). Collec-
tively, these data demonstrated the percentage of tissue staining
positive for ACE2 increased steadily from birth throughout child-
hood, peaking in adolescence and maintained through early
adulthood, followed by a decline in persons over 50 years of
age (Figure 4B). The ACE2-positive area did not appear different
for male versus female subjects (Figure 4B), but with n = 6 per
age group, statistical analysis was not performed and will be
the subject of future efforts.
Obesity is associated with an increased risk of COVID-19-
associatedmorbidity andmortality (Hussain et al., 2020;Nakesh-
bandi et al., 2020; Tartof et al., 2020). Taneera et al. (2020)
observed no relationship between ACE2 and BMI in isolated
pancreatic islets analyzed by microarray. To analyze this in situ,
we examined ACE2 protein expression in the aforementioned
six young adult donors together with pancreata from 16 addi-
tional donors (20–33 years of age, SARS-CoV-2 negative, no dia-
betes, for a total n=22)withBMI ranging fromnormal (19.5 kg/m2)
to obese (35.6 kg/m2) (Table S3). Notably, we observed a positive
correlation between ACE2-positive area and BMI (Figure 4C).
To more precisely visualize pancreatic ACE2 localization, we
performed IF staining for ACE2 (again using ab108252) in
conjunction with insulin and glucagon (Figures 4D–4F and S4B)
or with CD34 (Figure S4C). Across all ages, we observed ACE2
expression in the pancreatic ductal epithelium (Figure 4D), but
notmajor blood vessels (Figure S4B), based on their morphology
and geographic positioning. ACE2 was highly expressed in the
microvasculature within acinar and islet regions, with no evi-
dence of a cells or b cells expressing ACE2 protein (Figures
4E, 4F, S4A, and S4C). Our data corroborate findings by two
groups (Coate et al., 2020; Hikmet et al., 2020), yet contrast
with two others (Fignani et al., 2020; Yang et al., 2010). More-
over, our IHC analyses do not support the notion that islet endo-
crine cells may preferentially express a recently described short
ACE2 isoform (Fignani et al., 2020). Beyond this, we note that this
isoform lacks the SARS-CoV-2-binding domain (Blume et al.,
2020; Ng et al., 2020; Onabajo et al., 2020) and, thus, would
not render endocrine cells susceptible to infection. These dispa-
rate results may be influenced by technical (e.g., tissue process-
ing, antigen retrieval, reagent), material (e.g., isolated islets
versus tissue sections), or donor differences. However, in aggre-
gate, our analysis of 52 donors across a wide age and BMI range
provides a comprehensive perspective on pancreatic ACE2 pro-
tein distribution that demonstrates limited to no ACE2 expres-
sion by pancreatic endocrine cell types, including b cells (Figures
3 and 4), corroborating scRNA-seq and smFISH gene expres-
sion data (Figures 1 and 2).
SARS-CoV-2 NP Is Localized to Pancreatic Ductal
Epithelium from COVID-19 Cases With and Without T2D
Following autopsy, we reviewed pancreatic pathology by H&E-
stained sections in three individuals with fatal COVID-19 (aged
45–72 years; Figures 5A–5C), two of whom had a previous diag-
nosis of T2D (Table S4). Case 1 was an individual without history
of diabetes. The major findings included severe fatty replace-
ment of acinar cell mass and moderate arteriosclerosis (Fig-
ure 5A). Lobules contained fibrotic centers with residual acinar
cells and islets surrounding ductules (Figure 5A, insert). Islets
were observed primarily within fibrotic regions. Case 2was an in-
dividual with T2D whose pancreas had moderate fatty replace-
ment and limited centrolobular fibrosis (Figure 5B). Dystrophic
calcification of adipocytes was rare. We observed numerous is-
lets and one microthrombus without adjacent hemorrhage (Fig-
ure 5B, insert). The pancreas of another individual with T2D
(Case 3) showedmild tomoderate arteriosclerosis with acinar re-
gions containing mild centrolobular fibrosis (Figure 5C). Moder-
ate numbers of islets were present of varying sizes (Figure 5C,
insert). None of these individuals showed islet amyloidosis or
acute polymorphonuclear cell infiltrates. These histopathological
findings were compatible with the normal range of expected le-
sions within the exocrine compartment in pancreata from aged
persons and those with T2D.
IHC showed islets containing insulin-positive (INS+) b cells
with mostly spherical profiles, small to medium sizes, and vary-
ing proportions of b to a cells in all three cases (Figure 5D). We
observed numerous single and clustered INS+ and glucagon-
positive (GCG+) cells in ductules of fibrotic foci. The endothelium
showed moderate ACE2 staining intensity within both endocrine
and exocrine compartments. The ductal epithelium showed low
to moderate ACE2 staining intensity throughout the cytoplasm
(Figure S5A), similar to that observed in non-diabetic pancreas
donors (Figure 3C).
IHC for SARS-CoV-2 NP was also conducted to investigate
the cellular distribution of the virus. A lung sample from a person
with COVID-19 pneumonia was used to optimize staining condi-
tions. Immunopositive alveolar epithelial cells and macrophages
(B) Quantification of ACE2 protein expression in the pancreas of male (blue) and female (orange) control organ donors with ages ranging from birth to 72 years
shows progressive developmental changes. Data were analyzed by one-way ANOVA and Tukey’s post hoc test for multiple comparisons and are presented as a
percentage, *p < 0.05.
(C) Quantification of ACE2 protein expression in the pancreas of male (blue) and female (orange) control organ donors with BMI ranging from normal to obese; r =
0.81, n = 22, p < 0.001.
(D) Representative confocal images (from n = 14) of ACE2 protein expression in pancreatic ducts of control donors across the different age groups indicated.
Scale bars (left to right), 100, 200, 200, 300, 300, and 300 mm.
(E) Representative immunofluorescence images (n = 14) show ACE2 protein expression in pancreatic microvasculature from control donors across different age
groups. Scale bars, 100 mm.
(F) Representative immunofluorescence images (n = 14) of pancreatic islets showing ACE2 protein expression restricted to the islet’s microvasculature in
pancreata from control organ donors across different age groups. Scale bars, 50 mm.
Related to Table S3 and Figure S4.
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were observed with numerous viral inclusions (Figure S5B). In
COVID-19 Case 1, SARS-CoV-2 NP was present in some intra-
lobular and interlobular ductal epithelial cells shown near an islet
and widely scattered throughout the exocrine regions (Figures
5E, 5F, S5C, and S5D). Pancreata from Cases 2 and 3, who
had T2D, showed little to no immunopositivity for SARS-CoV-
2 NP.
We believe these data provide an important foundation for
considerations of pancreatic SARS-CoV-2 infection as a poten-
tial trigger for diabetes. Indeed, the notion of ACE2 expression
on pancreatic b cells as a potential mechanism linking the two
conditionsmay, in our view, promote a quasi-dogmatic perspec-
tive (Koch et al., 2020) that is grounded in limited experimental
evidence (Yang et al., 2010). However, the histopathology data
presented herein do not support a simple model of direct and
widespread islet endocrine, including b cell infection via the
ACE2 receptor. Rather, preferential ACE2 gene and protein
expression in microvascular and ductal structures suggests
these cells constitute a more likely target for viral infection, a
notion that is in principle supported by our observation of very
limited SARS-CoV-2 NP expression in ductal epithelium, but
not islet endocrine cells, of pancreata from individuals with
COVID-19. While scarce ACE2 protein expression and limited
SARS-CoV-2 propagation, as most recently documented for
the lung (Hönzke et al., 2020), do not preclude extensive tissue
damage mediated by innate immune responses in particular,
the absence of polymorphonuclear infiltrations in the three
COVID-19 pancreata interrogated here indicates a very limited
degree of inflammation consistent with that reported for many
tissues other than the lung and reticulo-endothelial system (Dor-
ward et al., 2020). More detailed investigations of pancreatic tis-
sue from fatal COVID-19 cases, to date a very limited resource,
will be necessary to answer outstanding questions about the po-
tential pathological involvement of the pancreas in COVID-19.
Limitations of Study
Our delineation, localization, and quantification of pancreatic
ACE2 is largely based on in silico and ex vivo in situ analyses
of gene (public scRNA-seq data, smFISH) and protein (IHC, IF)
expression in pancreata of a broad cohort of organ donors
without diabetes and a more limited number of organs collected
fromCOVID-19 autopsy subjects. As such, our pancreatic tissue
analyses can only provide approximate predictions regarding
ACE2 protein expression in isolated islets and islet cells or their
susceptibility to in vitro SARS-CoV-2 infection. Although the
aggregate scRNA-seq data demonstrate relatively little ACE2
mRNA in endocrine cells, Yang et al., in a wide-ranging report
on the development of a stem cell-based platform for SARS-
CoV-2 infection studies, recently demonstrated both ACE2 pro-
tein expression by endocrine cells in isolated human islets and
their productive infection with SARS-CoV-2 (Yang et al., 2020).
Without question and in addition to stem cell-derived endocrine
cells and islet organoids, isolated human islets constitute an
important model system for research discovery. Further work
will be needed to precisely quantify the fractions and expression
levels of ACE2 by islet endocrine cells in these islet preparations,
to evaluate possible modulation of ACE2 by the prolonged and
varied islet handling requirements (e.g., isolation, culture under
different conditions, dispersion), to define the exact role of
ACE2 in mediating SARS-CoV-2 infection in vitro and in vivo us-
ing extended islet xenotransplantation approaches, and to inter-
rogate the precise relation of scarce ACE2 expression and
immunopathology as most recently demonstrated for the lung
in a manuscript available for public review (Hönzke et al.,
2020). Beyond this, contrasting epidemiological reports from
the United Kingdom and Germany (Tittel et al., 2020; Unsworth
et al., 2020) not only underscore the requirement for data on dia-
betes incidence and SARS-CoV-2 infection rates in defined pop-
ulations over time, but in addition raise the need for studying
pancreatic tissues from donor cohorts of different demo-
graphics, ethnicities, and geographic populations. Indeed, it is
possible that COVID-19 may cause an upregulation of ACE2 in
endocrine or other cell types, but as of yet, gene and protein
expression levels cannot be reliably quantified from autopsy tis-
sues due to pancreatic autolysis and the relative scarcity of high-
quality pancreas tissues obtained from SARS-CoV-2-infected
individuals. Only in the larger context of expanded investigations
into pancreatic histopathology of individuals with COVID-19,
with carefully controlled in vitro infection studies, judicious use
of animal models to directly test the ability of SARS-CoV-2 to
infect the endocrine pancreas, and crucially, a balanced assess-
ment of emerging and future epidemiological studies (DiMeglio
et al., 2020) can we provide a complete framework for an
informed assessment of diabetes risk and potential prevention
in the wake of SARS-CoV-2 infection.
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Figure 5. Pathological Changes in Pancreata of Individuals with COVID-19
(A) Pancreas tissue section from COVID-19 Case 1 stained for H&E. Inset highlights fibrotic center with residual acinar cells and islet surrounding ductules. Scale
bars, 3 mm; inset, 200 mm.
(B) Pancreas tissue section from COVID-19 Case 2 stained for H&E. Inset highlights microthrombus without adjacent hemorrhages. Scale bars, 3 mm;
inset, 200 mm.
(C) Pancreas tissue section of COVID-19 Case 3 stained for H&E. Inset highlights a large, irregularly shaped pancreatic islet surrounded by fibrotic tissue. Scale
bars, 3 mm; inset, 200 mm.
(D) Representative pancreas tissue sections from three COVID-19 cases stained for ACE2, insulin (INS), and glucagon (GCG). Scale bars, 200 mm.
(E) SARS-CoV-2 NP observed in intralobular ducts (d) near an islet in the pancreas of COVID-19 Case 1. Scale bars, 10 mm.
(F) Representative image of multiple ducts showing SARS-CoV-2 NP positivity in the pancreas of COVID-19 Case 1. d; duct. Scale bar, 20 mm.
Related to Table S4 and Figures S5C and S5D.
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X., Zhu, J., Zhao, Z., Jaffré, F., et al. (2020). A human pluripotent stem cell-
based platform to study SARS-CoV-2 tropism and model virus infection in hu-
man cells and organoids. Cell Stem Cell 27, 125–136.e7.
Zang, R., Gomez Castro, M.F., McCune, B.T., Zeng, Q., Rothlauf, P.W.,
Sonnek, N.M., Liu, Z., Brulois, K.F., Wang, X., Greenberg, H.B., et al. (2020).
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small in-
testinal enterocytes. Sci. Immunol. 5, eabc3582.
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B.,
Gu, X., et al. (2020). Clinical course and risk factors for mortality of adult inpa-




Cell Metabolism 32, 1–11, December 1, 2020 11
Please cite this article in press as: Kusmartseva et al., Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Indi-
viduals with COVID-19, Cell Metabolism (2020), https://doi.org/10.1016/j.cmet.2020.11.005
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit monoclonal IgG anti-ACE2 (clone
EPR4435(2))
Abcam Cat# ab108252; RRID: AB_10864415
Rabbit polyclonal anti-ACE2 Abcam Cat# ab15348; RRID: AB_301861
Mouse monoclonal IgG2A anti-human
ACE2 (clone 171606)
R&D Systems Cat# MAB933; RRID: AB_2223153
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Biotinylated goat anti-rabbit IgG Vector Laboratories Cat# BA-1000; RRID: AB_2313606
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Fluor 488
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Invitrogen Cat# A-21202; RRID: AB_141607
IRDye 800CW Goat anti-rabbit IgG LI-COR Biosciences Cat# 926-32211; RRID: AB_621843
IRDye 800CW Goat anti-mouse IgG LI-COR Biosciences Cat# 926-32210; RRID: AB_621842
IRDye 800CW Donkey anti-goat IgG LI-COR Biosciences Cat# 926-32214; RRID: AB_621846
IRDye 680LT Donkey anti-mouse IgG LI-COR Biosciences Cat# 926-68022; RRID: AB_10715072
Biological Samples
Human control organ donor duodenum
blocks
nPOD; https://www.jdrfnpod.org/ Table S3
Human control organ donor kidney blocks nPOD; https://www.jdrfnpod.org/ Table S3
Human control organ donor pancreas
blocks
nPOD; https://www.jdrfnpod.org/ Table S3
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
ACE2 peptide Abcam Cat# ab198988
Antibody diluent reagent Life Technologies Cat# 003118
ImmpactDAB Vector Laboratories Cat# SK-4105
VECTASHIELD Antifade Mounting Medium
with DAPI
Vector Laboratories Cat# H-1200
Borg Decloaker RTU BioCare Medical Cat# BD1000G1
Background Sniper BioCare Medical Cat# BS966L
Protease inhibitor cocktail Thermo Fisher Scientific Cat# 78430
Phosphatase inhibitor cocktail Thermo Fisher Scientific Cat# 78428
Intercept Blocking Buffer LI-COR Biosciences Cat# 927-60001
Intercept Antibody Diluent LI-COR Biosciences Cat# 927-65001
ProLong Gold Antifade Mountant Thermo Fisher Scientific Cat# P36934




Avidin/Biotin blocking kit Vector Laboratories Cat# SP-2001
Elite standard detection kit Vector Laboratories Cat# PK-6100
MACH 2 Double Stain Kit 1 - Anti-Mouse
AP/Anti-Rabbit HRP
BioCare Medical Cat# MRCT523L
MACH 2 Double Stain Kit 2 - Anti-Mouse
HRP/ Anti-Rabbit AP
BioCare Medical Cat# MRCT525L
Betazoid DAB Chromogen Kit BioCare Medical Cat# BDB2004L
Warp Red Chromogen Kit BioCare Medical Cat# WR806
Ferangi Blue Chromogen Kit BioCare Medical Cat# FB813S
RNAscope Multiplex Fluorescent V2 Kit Advanced Cell Diagnostics Cat# 323100
TSA Plus Cyanine 3 Fluorescence Kit Perkin Elmer Cat# NEL744001KT
TSA Plus Cyanine 5 Fluorescence Kit Perkin Elmer Cat# NEL745001KT
Pierce BCA Assay kit Thermo Fisher Scientific Cat# 23227




Raw scRNaseq data generated using
inDrop
Gene Expression Omnibus Repository;
Baron et al., 2016
Table S1; GEO: GSE84133
Raw scRNaseq data generated using
Celseq
Gene Expression Omnibus Repository;
Gr€un et al., 2016
Table S1; GEO: GSE81076
Raw scRNaseq data generated using
Celseq2
Gene Expression Omnibus Repository;
Muraro et al., 2016
Table S1; GEO: GSE85241
Raw scRNaseq data generated using
Fluidigm C1
Gene Expression Omnibus Repository;
Lawlor et al., 2017
Table S1; GEO: GSE86469
Raw scRNaseq data generated using
SMART-Seq2
ArrayExpress; Segerstolpe et al., 2016 Table S1; E-MTAB-5061
Raw and analyzed histology data This paper https://aperioeslide.ahc.ufl.edu
Oligonucleotides
RNAscope Probe- Hs-ACE2 Advanced Cell Diagnostics Cat# 848151
RNAscope Probe- Hs-TMPRSS2-C2 Advanced Cell Diagnostics Cat# 470341-C2
RNAscope Probe- Hs-TMPRSS4-C2 Advanced Cell Diagnostics Cat# 565301
RNAscope Probe- Hs-TMPRSS11D-C2 Advanced Cell Diagnostics Cat# 870841-C4
RNAscope Probe- Hs-CTSL-C2 Advanced Cell Diagnostics Cat# 858611
RNAscope Probe- Hs-ADAM 17-C2 Advanced Cell Diagnostics Cat# 468141
(Continued on next page)
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for reagents may be directed to and will be fulfilled by the lead contact/corresponding author, Mark
A. Atkinson (atkinson@ufl.edu).
Materials Availability
This study did not generate new unique reagents. Tissues used in this study were obtained from the Network for Pancreatic Organ
donors with Diabetes (nPOD) and from autopsies performed on deceased individuals with COVID-19. nPOD tissues are freely avail-
able to approved investigators following successful application to the nPOD Tissue Prioritization Committee (TPC).
Data and Code Availability
This study did not generate code. Single cell sequencing data were obtained from the Gene Expression Omnibus (GEO) Repository:
GSE84133 (Baron et al., 2016), GSE81076 (Gr€un et al., 2016), GSE85241 (Muraro et al., 2016), and GSE86469 (Lawlor et al., 2017), as
well as fromArrayExpress: accession number E-MTAB-5061 (Segerstolpe et al., 2016). Original histology and additional de-identified
organ donor data are available from nPOD at the nPOD online digital pathology database and from the corresponding author upon
reasonable request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
nPOD Donors and Sample Processing
Transplant-quality pancreas, duodenum, and kidney were recovered by JDRF nPOD (https://www.jdrfnpod.org/) from 56 COVID-19
negative organ donors without diabetes (Table S3) according to established protocols and procedures (Campbell-Thompson et al.,
2012), as approved by the University of Florida Institutional Review Board (201400486), the United Network for Organ Sharing
(UNOS), and according to federal guidelines with informed consent obtained from each donor’s legal representative. Organs were
shipped in transport media on ice via organ courier to the nPOD Organ Pathology and Processing Core (OPPC) at the University
of Florida where tissues were processed (Campbell-Thompson et al., 2012). Medical chart andmedical-social questionnaire reviews
were performed, and T1D-associated autoantibodies measured by ELISA (Wasserfall et al., 2016) to confirm non-diabetic health sta-
tus. Donor demographics, hospitalization duration, and organ transport time were determined from hospital records or UNOS. This
study was not powered to statistically assess associations between ACE2 localization and donor sex.
Autopsy Subjects and Sample Processing
Pancreas was recovered from three individuals who tested positive for SARS-CoV-2 by reverse transcription polymerase chain re-
action (RT-PCR) test within 24-48 h of death at the University Medical Center NewOrleans (NewOrleans, LA), which is equipped with
an autopsy suite that meets U.S. Centers for Disease Control and Prevention standards for autopsy of persons with COVID-19 (Table
S4). Consent for autopsy without restriction was given by next of kin, and the studies within this report were determined to be exempt
from oversight by the Institutional Review Board at Louisiana State University Health Sciences Center.
METHOD DETAILS
Single-Cell RNA-Sequencing Data Analysis
Five human islet scRNA-seq datasets were obtained from publicly available repositories. These included four datasets from theGene
Expression Omnibus (GEO) Repository: GSE84133 (inDrop) (Baron et al., 2016), GSE81076 (Celseq) (Gr€un et al., 2016), GSE85241
(CelSeq2) (Muraro et al., 2016), andGSE86469 (FluidigmC1) (Lawlor et al., 2017). In addition, we analyzed an ArrayExpress database
under the accession number E-MTAB-5061 (SMART-Seq2) (Segerstolpe et al., 2016). For all scRNA-seq datasets, the same initial
normalization was performed: gene expression values for each cell were divided by the total number of transcripts and multiplied
by 10,000. Following log-transformation, cells were filtered that expressed fewer than 500 genes/cell (InDrops), 1,750 genes/cell (Cel-
Seq), or 2,500 genes/cell (CelSeq2, Fluidigm C1, and SMART-Seq2) in accordance with the methods employed in the original
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Software and Algorithms
Open-source Single-cell R Toolkit,
Seurat v.3
Satija Lab; Butler et al., 2018 http://satijalab.org/seurat/
HALO v3.0.311.262 Indica Labs https://indicalab.com/halo/
Other
Nitrocellulose membranes LI-COR Biosciences Cat# 926-31092
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corresponding publications, leaving 14,890 cells in total for the combined analysis. Pancreatic islet cell subtypes were identified us-
ing methods outlined in Butler et al. (2018).
To integrate scRNA-seq data, we applied canonical correlation analysis (CCA) in Seurat v.3 (Butler et al., 2018) using ‘‘FindInte-
grationAnchors’’ and ‘‘IntegrateData’’ functions. We chose the top 2,000 variable genes from each dataset to calculate the correla-
tion components (CCs) and ‘‘FindClusters’’ was utilized for shared nearest neighbor (SNN) graph-based clustering. Clusters were
visualized with t-distributed stochastic neighbor embedding (t-SNE) by running dimensionality reduction with ‘‘RunTSNE’’ and
‘‘TSNEPlot.’’ To compare the average gene expression within the same cluster between cells of different samples, we applied the
AverageExpression function. Statistical analyses are further described in Quantification and Statistical Analysis below. Violin plots
(VlnPlot) were used to visualize gene expression levels (Figures 1B, 1D, 1F, 1G, and S1). The ‘‘DotPlot’’ function was used to visualize
ACE2 and TMPRSS2 expression levels compared with cell type-enriched genes (Figure 1E).
Single Molecular Fluorescent In Situ Hybridization
To definemRNA expression patterns of SARS-CoV-2 associated genes in human pancreata, smFISHwas performed using the RNA-
scope Multiplex Fluorescent V2 kit (Advanced Cell Diagnostics, Newark, CA) in FFPE tissue cross-sections (5mm) from seven non-
diabetic, SARS-CoV-2 negative human organ donors from nPOD (Table S3; Figures 2A–2C andS2C–S2F). Slideswere baked at 60C
for 1 h, followed by dehydration with xylene for 5 min x 2 and 100% ethanol for 2 min at room temperature (RT). Next, slides were air-
dried at 60C for 5 min, treated with hydrogen peroxide for 10 min at RT, and washed 4 times with ddH2O, followed by antigen-
retrieval at 99C for 15 min. After another wash with ddH2O at RT for 15 s, slides were incubated at 100% ethanol for 3 min, air-dried
and then treated with protease plus for 30 min at 40C. Next, slides were hybridized with RNAscope Probes for TMPRSS2,
TMPRSS4, TMPRSS11D, CTSL, ADAM17 and ACE2mRNA, and detected using secondary TSA plus fluorophores (1:1500 dilution)
according to the manufacture’s protocol (Perkin Elmer, Waltham, MA). Slides were immediately washed with 1X PBS and PBS con-
taining 2% FBS for 5 min, blocked with donkey serum for 30 min, and incubated with ready to use (RTU) guinea pig polyclonal anti-
insulin (no dilution; Agilent Santa Clara, CA) and/or mousemonoclonal anti-CD34 antibody (1:1,000 dilution, Novus Biologicals) over-
night. The following morning, slides were washed with 1X PBS and PBS containing 2% FBS for 5 min and probed using either Alexa
Fluor (AF)-488 goat anti-guinea pig IgG (1:500 dilution, Invitrogen, Carlsbad, CA) or AF-488 donkey anti-mouse IgG (1:1,000 dilution,
Invitrogen) secondary antibodies. Finally, the slides were washed with PBS, counterstained with DAPI, and mounted with a coverslip
using ProLong Gold antifade mounting media (Thermo Fisher, Rockford, IL). Images were acquired using an LSM800 confocal mi-
croscope (Carl Zeiss, Germany).
Tissue Homogenization
Pancreas tissues were homogenized in modified radioimmunoprecipitation (RIPA) buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl,
5 mM EDTA, 1 mM EGTA, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) with freshly prepared protease and phosphatase
inhibitor cocktails (Thermo Fisher Scientific) using a Tissue Tearor (BioSpec, Bartlesville, OK). After homogenization, tissue was
further disrupted with a Vibra-Cell sonicator (Sonics & Materials, Newtown, CT) for 15 s, placed on ice for 15 min, then sonicated
again and placed on ice for another 15 min. The tissue homogenates were centrifuged at 14,000 x g for 20 min at 4C, and the su-
pernatants were assayed for total protein concentration using a Pierce BCA Assay kit (Thermo Fisher Scientific) and stored at80C
until use.
Western Blotting
Fifty micrograms of protein lysates in Laemmli’s buffer containing 2.5% b-mercaptoethanol were boiled at 100C for 5 min prior to
loading into a 4%–20%gradient Mini-PROTEAN TGXStain-Free gel (Bio-Rad, Hercules, CA). After protein separation, gels were acti-
vated using a Gel DOC EZ imager (Bio-Rad), then transferred onto nitrocellulose membranes (LI-COR Biosciences, Lincoln, NE).
Following protein transfer, membranes were scanned with the Gel DOC EZ imager, and total protein staining was visualized and
quantified using Image Lab software version 5.2.1 (Bio-Rad). Then, membranes werewashed and blocked for 1 h at RTwith Intercept
Blocking Buffer (LI-COR Biosciences). Thereafter, the membranes were incubated at 4C overnight with one of four primary anti-
bodies (rabbit monoclonal anti-ACE2 (1:1,000 dilution, Abcam, Cambridge, MA), rabbit polyclonal anti-ACE2 (1:500 dilution, Abcam),
mouse monoclonal anti-ACE2 (1:1,000 dilution, R&D Systems), goat polyclonal anti-ACE2 (1:500 dilution, R&D Systems, Minneap-
olis, MN)) andmouse monoclonal anti-b-actin (1:10,000 dilution; Sigma-Aldrich, St. Louis, MO) in Intercept Antibody Diluent (LI-COR
Biosciences). The membranes were then washed with Tris-buffered saline containing 0.1% Tween 20 (TBST) three times at 5 min
intervals, incubated with secondary antibodies (IRDye 800CWgoat anti-rabbit IgG (1:30,000 dilution), IRDye 800CWgoat anti-mouse
IgG (1:30,000 dilution), IRDye 800CWdonkey anti-goat IgG (1:30,000 dilution), or IRDye 680LT donkey anti-mouse (1:40,000 dilution),
all from LI-COR Biosciences) for 1 h at RT. The membranes were washed three times with TBST at 5-min intervals. Immunoreactive
bands were visualized and densitometrically analyzed using Odyssey infrared scanner and Image Studio software version 3.1 (LI-
COR Biosciences) (Figures 3B, S3A, and S3B).
Immunohistochemistry
FFPE pancreas, duodenum, and kidney tissues were sectioned (4mm), deparaffinized, rehydrated by serially passing through
changes of xylene and graded ethanol, subjected to heat induced antigen retrieval in 10mM Citra pH 6, and blocked with avidin,
biotin, and goat serum. For single-stained kidney and duodenum tissue sections (Figure S3C) and for SARS-CoV-2 NP single stained
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lung and pancreas sections (Figures 5E, 5F, S5B, and S5C), slides were incubated overnight at 4C with one of four primary anti-
bodies against ACE2 (rabbit monoclonal anti-ACE2, 1:200 dilution (Abcam); rabbit polyclonal anti-ACE2, 1:2,000 dilution (Abcam);
mouse monoclonal anti-human ACE2, 1:100 dilution, (R&D Systems); goat polyclonal anti-ACE2, 1:100 dilution, (R&D Systems))
or a primary antibody against SARS-CoV-2 NP (mouse monoclonal anti-SARS-CoV-2 NP, 1:50 dilution, Invitrogen). Slides were
washed, then incubated for 30min at RTwith biotinylated secondary antibodies (biotinylated goat anti-rabbit IgG, 1:200 dilution (Vec-
tor Laboratories, Burlingame, CA); biotinylated horse anti-mouse IgG, 1:200 dilution (Vector Laboratories); biotinylated rabbit anti-
goat, 1:200 dilution (Vector Laboratories)), and developed with ImmpactDAB (Vector Laboratories) followed by hematoxylin
counterstain.
For peptide blocking experiments (Figure S3D) the primary antibody (monoclonal rabbit anti-ACE2, 1:100 dilution (Abcam)) was
incubated with 1mg/mL ACE2 peptide (Abcam) for 1 h at RT, before applying to pancreas slides for overnight incubation at 4C.
Thereafter, IHC methodology was carried out as described for single stained sections.
For double- and triple-stained slides, FFPE pancreas slides were prepared for heat induced antigen retrieval in Borg Decloaker RTU
(BioCareMedical, Pacheco, CA) followed by 3%H2O2. After washing, tissues were blocked with Background Sniper (BioCareMedical)
followed by staining. For insulin and ACE2 double-staining (Figures 3C, 4A, and S4B), blocked slides were incubated for 20 min at RT
with the first primary antibody (rabbit monoclonal anti-ACE2, 1:200 dilution (Abcam)), then washed and incubated withMACH 2 Double
Stain Kit 1 (BioCare Medical) for 20 min at RT. Slides were washed and developed using DAB Chromogen solution (BioCare Medical),
then subjected to a second round of heat-induced antigen retrieval in Borg Decloaker RTU, followed by 3%H2O2. After washing, slides
were again blocked with Background Sniper, washed, and incubated with the second primary antibody (rabbit monoclonal anti-insulin,
1:2,000 dilution (Abcam)) for 30 min at RT. After washing, slides were incubated with MACH 2 Double Stain Kit 2 for 30 min at RT,
washed, and developed with Warp Red Chromogen solution (BioCare Medical) followed by Hematoxylin counterstain. For SARS-
CoV-2 NP and cytokeratin 19 double-staining (Figure S5D), slides were incubated with primary antibody against SARS-CoV-2 NP
(mouse monoclonal anti-SARS-CoV-2 NP, 1:50 dilution, Invitrogen overnight. Slides were washed, then incubated for 30 min at RT
with biotinylated secondary horse anti-mouse IgG, 1:200 dilution (Vector Laboratories) and developed with ImmpactDAB (Vector Lab-
oratories). Next, slides were subjected to a second round of heat-induced antigen retrieval in Borg Decloaker RTU, followed by 3%
H2O2. After washing, slides were again blocked with Background Sniper, washed, and incubated with the second primary antibody
(mousemonoclonal anti-cytokeratin 19, 1:50 dilution, Agilent) for 3min at RT. After washing, slideswere incubatedwithMACH2Double
Stain Kit 1 for 20 min at RT, washed, and developed with Ferangi Blue Chromogen solution (BioCare Medical).
For ACE2, insulin and glucagon triple-staining (Figure 5D), blocked slides were incubated for 20 min at RT with a primary antibody
cocktail (mousemonoclonal anti-glucagon, 1:1,000 dilution (Abcam) plus rabbit monoclonal anti-ACE2, 1:200 dilution (Abcam)), then
washed and incubated with MACH 2 Double Stain Kit 1 (BioCare Medical) for 20 min at RT. Slides were washed and developed using
DAB Chromogen solution for ACE2 visualization followed by Ferangi Blue Chromogen solution (BioCare Medical) for glucagon visu-
alization. Slides were then subjected to a second round of heat-induced antigen retrieval in Borg Decloaker RTU, followed by 3%
H2O2. After washing, slides were again blockedwith Background Sniper, washed, and incubated with the third primary antibody (rab-
bit monoclonal anti-insulin, 1:2,000 dilution (Abcam)) for 30 min at RT. After washing, slides were incubated with MACH 2 Double
Stain Kit 2 for 30 min at RT, washed, and developed with Warp Red Chromogen solution (BioCare Medical) followed by Hematoxylin
counterstain.
Following single-, double-, or triple-IHC staining, whole slides were scanned at an absolute magnification of 20x using an Aperio
CS2 Scanscope (Leica/Aperio, Vista, CA), and stored in the nPOD online digital pathology database (eSLIDE version 12.4.0.5043,
Leica/Aperio). Images were taken using Aperio ImageScope v12.4.3 or a Keyence BZ-X700 microscope.
Immunofluorescence
For immunofluorescence staining, FFPE pancreas sections were sectioned (4mm), deparaffinized, and rehydrated with antigen
retrieval in 10mM Citra pH 6 and blocking as described above for IHC. Slides were incubated overnight at 4C with primary anti-
bodies: a) monoclonal rabbit anti-ACE2 (1:100 dilution; Abcam), polyclonal guinea pig anti-insulin RTU antibody (undiluted; Agilent),
and monoclonal mouse anti-glucagon (dilution; 1:20,000 Abcam) (Figures 4D–4F) or b) monoclonal rabbit anti-ACE2 (1:100 dilution;
Abcam) and monoclonal mouse anti-CD34 (dilution 1:1,000; Novus Biologicals, Centennial, CO) (Figure S4C). Slides were washed,
then incubated for 45 min at RT in the dark with secondary antibodies: a) goat anti-rabbit IgG-AF555, goat anti-mouse IgG-AF488,
and goat anti-guinea pig IgG-AF647, or b) goat anti-rabbit IgG-AF594 and goat anti-mouse IgG-AF488 (all from Invitrogen). Slides
were washed, then counterstained with DAPI and viewed using a Keyence BZ-X700 automated fluorescence microscope.
H&E Staining
H&E staining was performed on FFPE pancreas tissues sections (4mm) from the three COVID-19 autopsy subjects according to stan-
dard methodology. Whole slides were scanned using an Aperio CS2 Scanscope (Leica/Aperio, Vista, CA), and stored in the nPOD
online digital pathology database (eSLIDE version 12.4.0.5043, Leica/Aperio). Images were taken using Aperio ImageScope v12.4.3.
QUANTIFICATION AND STATISTICAL ANALYSIS
For scRNA-seq analysis, n represents the number of cells as indicated in the figure legends. Analyses were performed in R as
described in Method Details above. Differences in the average gene expression levels between pancreatic cell subsets or within
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each cell subset from non-diabetic donors versus donors with T2D were compared using Wilcoxon rank sum tests, requiring a min-
imum 1.19-fold change between the two groups and expression in at least 10% of cells from either group. Bonferroni corrections
were used to adjust for multiple comparisons. Paired Student’s t tests were used to compare proportions of cells with detectable
gene expression. p values < 0.05 were considered significant. Violin plot limits show maxima and minima, and the dots represent
individual data points. smFISH data were not quantitatively evaluated. For the quantification of ACE2 protein expression throughout
the human lifespan and for the analysis of correlation between ACE2 protein expression and BMI, digitized images of ACE2 and in-
sulin co-stained slides were analyzed using the HALO quantitative image analysis platform V3.0.311.262 (Indica Labs, Corrales, NM)
(Figure 4A). The annotation pen tool was used to outline the tissue section to determine total tissue area (mm2). The Area quantifi-
cation algorithm v2.1.3 based on red, blue, green (RBG) spectra was employed to detect ACE2 positive tissue area stained for
3,30-Diaminobenzidine (DAB, brown). The algorithm detected DAB IHC positivity and calculated percentage of ACE2 positive area
per total tissue area. For the ACE2 expression as factor of age study, BMI-matched donors (n = 36) were binned into six age groups
representing major stages of human life: neonatal (0-0.25 years), infant and toddler (0.25-2 years), childhood (2-11 years), puberty
(11-15 years), young adult (20-33 years), and senior adult (51-72 years). Data were analyzed in GraphPad Prism v8.3 (GraphPad Soft-
ware, San Diego, CA) by one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons with significance defined as p <
0.05 and graphed with the median percent ACE2 area shown for each group in a box and whisker plot. To assess for an association
between ACE2 expression and BMI, we reviewed the 34 nPOD donors aged 20-33 years without diabetes with samples available and
selected those without significant underlying pancreatic pathology. This resulted in evaluation of 22 adult organ donors with BMI
ranging from 19.5-35.6 kg/m2; data were analyzed in R using Spearman’s correlation test. All image analysis data were collected
in blinded fashion. The remaining IF and IHC data were not quantitatively evaluated.
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